NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis $0.84 +0.02 (+2.66%) Closing price 04:00 PM EasternExtended Trading$0.84 0.00 (-0.12%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cue Biopharma Stock (NASDAQ:CUE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cue Biopharma alerts:Sign Up Key Stats Today's Range$0.82▼$0.8950-Day Range$0.65▼$0.9152-Week Range$0.45▼$1.99Volume198,096 shsAverage Volume130,539 shsMarket Capitalization$64.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Read More Cue Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreCUE MarketRank™: Cue Biopharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 487th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cue Biopharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cue Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of Cue Biopharma has been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cue Biopharma has recently decreased by 22.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.58 Percentage of Shares Shorted1.28% of the float of Cue Biopharma has been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cue Biopharma has recently decreased by 22.24%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.43 News SentimentCue Biopharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cue Biopharma this week, compared to 1 article on an average week.Search Interest5 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows1 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders12.26% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUE Stock News HeadlinesLUCID CAPITAL MARKETS Initiates Coverage of Cue Biopharma (CUE) with Buy Recommendation3 hours ago | msn.comRecurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and CompaniesAugust 25 at 11:02 PM | theglobeandmail.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 26 at 2:00 AM | Investors Alley (Ad)Cue Biopharma initiated with a Buy at Lucid CapitalAugust 25 at 12:58 PM | msn.comCue Biopharma to Present Program Updates at Cantor Global Healthcare Conference 2025August 21, 2025 | quiverquant.comQCue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare ConferenceAugust 21, 2025 | globenewswire.comCue Biopharma announces initiation of investigator sponsored trial of CUE-102August 13, 2025 | msn.comCue Biopharma, Inc.: Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 13, 2025 | finanznachrichten.deSee More Headlines CUE Stock Analysis - Frequently Asked Questions How have CUE shares performed this year? Cue Biopharma's stock was trading at $1.09 on January 1st, 2025. Since then, CUE shares have decreased by 22.9% and is now trading at $0.84. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. The business earned $2.95 million during the quarter, compared to analysts' expectations of $2 million. Cue Biopharma had a negative net margin of 469.35% and a negative trailing twelve-month return on equity of 230.13%. Who are Cue Biopharma's major shareholders? Cue Biopharma's top institutional investors include GC Wealth Management RIA LLC (4.42%), Angeles Wealth Management LLC (0.16%), Northwestern Mutual Wealth Management Co. (0.11%) and Group One Trading LLC. Insiders that own company stock include Daniel R Passeri, Anish Suri and Peter A Kiener. View institutional ownership trends. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT). Company Calendar Last Earnings8/12/2025Today8/26/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CUE CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees60Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.67 million Net Margins-469.35% Pretax Margin-469.35% Return on Equity-230.13% Return on Assets-111.16% Debt Debt-to-Equity Ratio0.01 Current Ratio1.60 Quick Ratio1.60 Sales & Book Value Annual Sales$9.29 million Price / Sales6.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book3.50Miscellaneous Outstanding Shares76,850,000Free Float67,425,000Market Cap$64.55 million OptionableOptionable Beta1.53 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:CUE) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.